Urethral Adenocarcinoma — Trials

Urethral Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03866382	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	recruiting	Phase 2	314	National Cancer Institute (NCI)NIH	2	Sep 24, 2026	clinicaltrials
NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	active not recruiting	Phase 2	798	National Cancer Institute (NCI)NIH	2	Jun 17, 2026	clinicaltrials